Last updated on July 2020

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

Brief description of study

To investigate the safety and efficacy of an orally administered dose of TW-012R in patients with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo group as a control. In addition, long-term safety will be examined in an open-label extension trial.

Clinical Study Identifier: NCT04413344

Find a site near you

Start Over

Osaka University

Suita, Japan
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.